COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Mirena or Conventional Medical Treatment for Menorrhagia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00864136
Recruitment Status : Completed
First Posted : March 18, 2009
Last Update Posted : July 1, 2015
Information provided by (Responsible Party):

Brief Summary:

The aim of this prospective, non-interventional post-marketing surveillance study is to obtain data on safety and efficacy of Mirena in treatment of prolonged or heavy menstrual bleeding (Menorrhagia) under daily-life treatment conditions.

It is planned to conduct the study in about 10 countries with a total of 1000 patients. In several countries, a comparator group will also be documented.

For each patient, an initial visit and one to three follow-up visits after about 3, 6 and 12 months will be documented by the treating physician on the case report form. Observations include the patient's demographic parameters (date of birth, height, weight, race and smoking habits), previous contraceptives and menorrhagia treatment, gynaecological history, baseline menstruation, result of insertion, concomitant medications and diseases as well as menorrhagia symptoms. Overall treatment success will be evaluated at the end of treatment including number of weeks until improvement and reduction of menstrual bleeding with respect to duration and severity, and patient's satisfaction.

Condition or disease Intervention/treatment
Menorrhagia Drug: Levonorgestrel (Mirena, BAY86-5028) Drug: Conventional medical treatment

Detailed Description:

The "MiCo - Mirena or conventional medical treatment for menorrhagia" study consist of two parts, MiCo Asia-Pacific and MiCo MA0901 (Rest of World).

Data from both parts will be analysed in separate pools as well as in a global pool. The trial alias are IMPACT Nos. 14697, 14536 (NCT01085487).

Layout table for study information
Study Type : Observational
Actual Enrollment : 647 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: MiCo - Mirena or Conventional Medical Treatment for Menorrhagia
Study Start Date : November 2008
Actual Primary Completion Date : November 2010
Actual Study Completion Date : November 2010

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Group 1 Drug: Levonorgestrel (Mirena, BAY86-5028)
Women using Mirena for treatment of menorrhagia

Group 2 Drug: Conventional medical treatment
Women using combined oral contraceptives, oral/injectable progestogens, non-steroidal anti-inflammatory drug

Group 3 Drug: Conventional medical treatment
Women using anti-fibrinolytic agent for treatment of menorrhagia

Primary Outcome Measures :
  1. Cumulative continuation rate stratified by history of previous treatment(s) for menorrhagia [ Time Frame: at 12 months ]

Secondary Outcome Measures :
  1. Bleeding pattern [ Time Frame: at 12 months ]
  2. Patient satisfaction at end of documentation [ Time Frame: at 12 months ]
  3. Impact of the therapy in terms of patient-derived health outcomes (validated patient questionnaire) [ Time Frame: at 12 months ]
  4. Adverse events collection [ Time Frame: at 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Women with a diagnosis of idiopathic menorrhagia can be enrolled after decision for treatment has been made.

Inclusion Criteria:

  • Women between the ages of 18-45 (inclusive) not intending to get pregnant during the next year
  • Women complaining of heavy menstrual bleeding over several consecutive cycles
  • Women without structural or histological abnormality of the uterus, or with fibroids less than 3 cm in diameter which are causing no distortion of the uterine cavity (eligible for pharmaceutical treatment according to the NICE guideline 2007)
  • Informed consent (where required by laws or regulations)

Exclusion Criteria:

  • The contraindications and warnings of the respective Summary of Product Characteristics (Mirena, combined oral contraceptives, oral/injectable progestogens, non-steroidal anti-inflammatory drug, or anti-fibrinolytic agent) must be followed.
  • Women taking hormone replacement therapy
  • Women with symptoms such as intermenstrual or post-coital bleeding, unless an endometrial biopsy has been performed and pathology excluded
  • Women with fibroids that are palpable abdominally or who have intra-cavity fibroids and/or whose uterine length as measured at ultrasound or hysteroscopy is greater than 12 cm (NICE guideline 2007)
  • Women on anticoagulative therapy or other treatment (including e.g. Copper IUD use) known to cause menorrhagia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00864136

Layout table for location information
Many Locations, China
Hong Kong
Many Locations, Hong Kong
Many Locations, Indonesia
Korea, Republic of
Many Locations, Korea, Republic of
Many Locations, Malaysia
Many Locations, Pakistan
Many Locations, Taiwan
Many Locations, Thailand
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Bayer Identifier: NCT00864136    
Other Study ID Numbers: 14697
MA0701 ( Other Identifier: Company Internal )
MA0901 - non-East Asia ( Other Identifier: Company Internal )
First Posted: March 18, 2009    Key Record Dates
Last Update Posted: July 1, 2015
Last Verified: June 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Hemorrhage
Uterine Diseases
Pathologic Processes
Menstruation Disturbances
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptives, Oral, Synthetic
Contraceptives, Oral